Lee D S, Wong H A, Knoppert D C
Department of Paediatrics, St. Joseph's Health Centre, Lawson Research Institute, University of Western Ontario, London, Canada.
Biol Neonate. 1994;66(6):311-5. doi: 10.1159/000244123.
Lorazepam is being used with increasing frequency as a sedative in the newborn and the young infant. Concern has been raised with regard to the safety of lorazepam in this age group, especially in very-low-birth-weight (VLBW; < 1,500 g) infants. Three young infants, all of birth weight < 1,500 g, experienced myoclonus following the intravenous administration of lorazepam. The potential neurotoxic effects of the drug (and its vehicle) in this population are discussed. Injectable lorazepam should be used with caution in VLBW infants.
劳拉西泮作为新生儿和小婴儿的镇静剂，其使用频率越来越高。人们对该年龄组使用劳拉西泮的安全性表示担忧，尤其是在极低出生体重（VLBW；<1500g）的婴儿中。三名出生体重均<1500g的小婴儿在静脉注射劳拉西泮后出现了肌阵挛。本文讨论了该药物（及其溶媒）在这一人群中的潜在神经毒性作用。极低出生体重婴儿使用注射用劳拉西泮时应谨慎。
